Dr. John F. De Groot, MD

Dr. De Groot practices at UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health.

Dr. De Groot's NPI, 1316045008, was assigned on September 20, 2006. Dr. De Groot graduated from UTMB Health in 1998. Dr. De Groot holds Texas license L3278.

Dr. De Groot's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights, at 505 Parnassus Ave, Box 0296, San Francisco, CA 94143 in San Francisco County. The practice phone is (415) 353-2733.

Dr. De Groot's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health. Dr. De Groot is also affiliated with The University of Texas MD Anderson Cancer Center. The medical group on file is UCSF Pediatrics. Dmand AI also links Dr. De Groot to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. De Groot practices, 2 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. De Groot's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. De Groot is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. De Groot's licenses on file in 2 states: Texas and California.

Dmand AI lists head injury among the conditions Dr. De Groot treats.

CMS data shows 349 Medicare services from Dr. De Groot across 5 procedure codes in 2024, for 76 Medicare patients. Medicare paid $24,734 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 76 Medicare patients who saw Dr. De Groot in 2024. The largest group is 65 to 74, with 38 patients. 55% of them have high blood pressure, and 47% have high cholesterol. 16% are also on Medicaid. Their average risk score is 1.93, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. De Groot's median patient age at 57, with 42% women.

In 2024, Dr. De Groot wrote 120 Medicare Part D claims for 35 patients. 95% of them were for generic drugs. CMS names the drug for 22 of them, across 1 drug with 11 or more claims each, at $1,402 in total drug cost. In 2023, CMS named 35 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. De Groot for performance year 2024, reported as part of a group. Dr. De Groot accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. De Groot as offering telehealth.

Dmand AI links 131 papers to Dr. De Groot, published from 2008 to 2023. 2019 was the busiest year, with 11. The most frequent topics are Brain Neoplasms, Glioblastoma and Glioma. Dr. De Groot has published most often in Neuro Oncol. Dr. De Groot's most frequent co-authors are Wai-Kwan A. Yung, MD, Gregory N. Fuller, MD, PhD and Nazanin K. Majd, MD.

CMS Open Payments shows 201 general payments to Dr. De Groot from 23 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 77% of the total. Telix Pharmaceuticals paid the most, $59,210. It also lists 10 research payments totaling $5,529 from 2023 to 2025.

Dr. De Groot graduated from UTMB Health in 1998. Dr. De Groot is a member of ASCO.

Dr. De Groot is in network with 11 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.